Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?

Current opinion in pharmacology 2024 Vol.78() p. 102476

Matak I, Lacković Z

관련 도메인

Abstract

Driven by the clinical success of botulinum toxin serotype A (BoNT/A) and the need for improved chronic pain management, researchers attempted to develop re-designed botulinum toxin (BoNT)-based molecules as novel analgesics. Various recombinant protein expression strategies including retargeted binding domains, and chimeric toxins combining different serotypes were tested to improve BoNT/A therapeutic safety margin and expand its efficacy. The aim of this review is to re-evaluate the current design strategies for recombinant BoNT-based molecules for pain treatment, compares their analgesic profile against the native BoNT/A, as well as to discuss the main strengths and potential weaknesses of reported approaches.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 3
질환 pain C0030193
Pain
scispacy 1
기타 BoNT/A → botulinum toxin serotype A scispacy 1

MeSH Terms

Humans; Botulinum Toxins, Type A; Animals; Pain; Analgesics; Recombinant Proteins

📑 인용 관계

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문